These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 38377034)
1. Immune checkpoint inhibitor-related colitis in patients on immunotherapy for cancer. Sun BL; Elliott AS; Nolte D; Sun X Am J Clin Pathol; 2024 Jul; 162(1):17-27. PubMed ID: 38377034 [TBL] [Abstract][Full Text] [Related]
2. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach. Del Gaudio A; Di Vincenzo F; Petito V; Giustiniani MC; Gasbarrini A; Scaldaferri F; Lopetuso LR Inflamm Bowel Dis; 2024 Jun; 30(6):1018-1031. PubMed ID: 37801695 [TBL] [Abstract][Full Text] [Related]
3. Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis. Wang J; Guo Z; Shen M; Xie Q; Xiang H Front Immunol; 2024; 15():1366489. PubMed ID: 38660314 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Westdorp H; Sweep MWD; Gorris MAJ; Hoentjen F; Boers-Sonderen MJ; van der Post RS; van den Heuvel MM; Piet B; Boleij A; Bloemendal HJ; de Vries IJM Front Immunol; 2021; 12():768957. PubMed ID: 34777387 [TBL] [Abstract][Full Text] [Related]
5. Immune mechanisms of toxicity from checkpoint inhibitors. Wang SJ; Dougan SK; Dougan M Trends Cancer; 2023 Jul; 9(7):543-553. PubMed ID: 37117135 [TBL] [Abstract][Full Text] [Related]
7. The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application. Han X; Zang D; Liu D; Chen J Front Immunol; 2022; 13():988849. PubMed ID: 36189293 [TBL] [Abstract][Full Text] [Related]
9. The colitis may be microscopic, but the diarrhea is not: update on the treatment of microscopic colitis and immune checkpoint inhibitor colitis. Enwerem NY; Yen EF Curr Opin Gastroenterol; 2024 Jan; 40(1):50-59. PubMed ID: 37874119 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Assarzadegan N; Montgomery E; Anders RA Virchows Arch; 2018 Jan; 472(1):125-133. PubMed ID: 29143108 [TBL] [Abstract][Full Text] [Related]
11. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. Yao J; Li M; Zhang H; Ge Y; Weygant N; An G Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598 [TBL] [Abstract][Full Text] [Related]
12. Gut microbiota shed new light on the management of immune-related adverse events. Tan B; Liu YX; Tang H; Chen D; Xu Y; Chen MJ; Li Y; Wang MZ; Qian JM Thorac Cancer; 2022 Oct; 13(19):2681-2691. PubMed ID: 36043345 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis. Hone Lopez S; Kats-Ugurlu G; Renken RJ; Buikema HJ; de Groot MR; Visschedijk MC; Dijkstra G; Jalving M; de Haan JJ Virchows Arch; 2021 Dec; 479(6):1119-1129. PubMed ID: 34338882 [TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. Tang L; Wang J; Lin N; Zhou Y; He W; Liu J; Ma X Front Immunol; 2021; 12():800879. PubMed ID: 34992611 [TBL] [Abstract][Full Text] [Related]
15. New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis. Velikova T; Krastev B; Gulinac M; Zashev M; Graklanov V; Peruhova M World J Clin Cases; 2024 Feb; 12(6):1050-1062. PubMed ID: 38464930 [TBL] [Abstract][Full Text] [Related]
16. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146 [TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. Dougan M Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493 [TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal Tract Adverse Events. Abu-Sbeih H; Wang Y Adv Exp Med Biol; 2020; 1244():247-253. PubMed ID: 32301019 [TBL] [Abstract][Full Text] [Related]
19. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210 [TBL] [Abstract][Full Text] [Related]
20. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]